en <p style="text-align:justify"><span style="font-size:11pt"><span style="font-size:10.0pt">Prostate cancer (PCa) is the second leading cause of cancer death in men. About one in 39 will die of prostate cancer and about one man out of seven is diagnosed with the problem. The expression of the Epidermal Growth Factor Receptor (EGFR) is shown in the progression of androgen independent PCa. EGFR has emerged as a promising therapeutic target for patients with castration‑resistant PCa. There is an urgent need for detection of EGFR expression and monitoring the treatment in prostate cancer. Affibodies&nbsp;are small engineered proteins with a high affinity to a large number of target proteins or peptides. Affibodies are three-helix bundles of 58 amino acids based on Z domain of staphylococcal protein A; ZHER2 is one of them with the high-affinity to Human Epidermal growth factor Receptor 2 (HER2). Positron Emission Tomography (PET) imaging with 18F-Labeled ZHER2: 2891 affibody can be a good candidate for prostate cancer detection.</span></span></p> Prostate cancer, Positron Emission Tomography (PET), ZHER2 affibody 171 171 https://www.ajmb.org/En/Article.aspx?id=40470 https://www.ajmb.org/PDF/En/FullText/40470.pdf MahboobehNazari11474RaminRadmaneshDepartment of Pharmacoeconomics and Pharmaceutical Management, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran61738